In experimental tumor immunotherapy, incomplete Freund's adjuvant (lFA) has been considered as the "gold standard" for Tcell vaccination in mice and humans in spite of its considerable adverse effects. Recently, we succeeded in eliciting strong CTl responses in mice after vaccination with biodegradable poly(o,L-lactide-co-glycolide) (PlGA) microspheres (MS). In our study, we compared the immune response to IFA and PlGA-MS containing ovalbumin (OVA) and CpG-oligodeoxynucleotide (MS-OVA/CpG) or we used a mixture of MS-OVA/CpG and MS-polyl:C. A single vaccination with MS-OVA/CpG elicited longlasting titers of IgGl and IgG2a, but only low IgE titers, and also the T-cell response was biased toward Thl differentiation. Antigen presentation to C04+ and C08 + cells and activation of a cytotoxic T-cell response in mice vaccinated with PlGA-MS and IFA lasted for over 3 weeks. Preconditioning of the injection site with TNF-ex and heterologous prime-boost regimen further enhanced the cytotoxic response. PlGA-MS were as efficient or superior to IFA in eradication of preexisting tumors and suppression of lung metastases. Taken together, PlGA-MS are well-defined, biodegradable and clinically compatible antigen carrier systems that compare favorably with IFA in their efficacy of tumor immunotherapy in mouse models and hence deserve to be tested for their effectiveness against human malignant diseases.
antigens have to be delivered for cross presentation on MHC class I molecules and direct presentation on MHC class II molecules,! To achieve an effective T-cell stimulation, it is beneficial if antigen and adjuvant reach the same endosome,2,) which makes their joint uptake highly desirable,
The progress in the development of antigen delivery systems that achieve this aim is lagging behind, thereby hampering a successful introduction of immunotherapy into clinical practice. For numerous clinical trials, antigens and pattern molecules are incorporated into a formulation, which has been introduced over 60 years ago, i.e., incomplete Freund's adjuvant (IFA).4 IFA is a water-in-oil emulsion, which can be mixed with antigens and pattern molecules. Although IFA/ antigen emulsions elicit long-lasting IgG responses, they also stimulate the activation of CTL and T-helper cells. s , 6 In spite of such desired properties, IFA is not approved for routine immunotherapy in humans, but is merely used in investigational clinical trials. Recent studies described severe local skin reactions, sterile abscesses and cysts, inflammations and persistent painful granulomas at the injection site, when using IFA or a formulation similar to IFA (Montanide ISA-51) ? Moreover, oil-induced neoplasms have been observed. 8 The need to develop potent and well-defined antigen delivery systems is therefore self-evident.
We and other groups have investigated microspheres (MS) consisting of polY(D,L-lactide-co-glycolide) (PLGA) as antigen delivery system targeting dendritic cells (DCs) and macrophages in vitro and in vivo. use in humans. e.g.. for delivering drugs and as material for biodegradable surgical sutures. 14 PLGA can be used to microencapsulate peptides. proteins. RNA or DNA by several procedures. such as spray drying. which produces MS of a size of 1-5 ~lm.1 5 Such size range is ideal for the phagocytic uptake by DC in vitro. '6 PLGA hydrolyses in aqueous environment during several weeks thereby releasing slowly microencapsulated substances. Uptake of PLGA-MS by human monocyte-derived DC in vitro does not negatively affect their survival. migration. cytokine release or T-cell stimulation. 16 After being ingested by DC. PLGA-MS release microencapsulated antigens intracellularly for processing and presentation on MHC class I and II molecules. 17 Especially. cross presentation may be at least a 100-fold more sensitive in vitro if the antigen is taken up in association with PLGA-MS when compared to a soluble form .
On the basis of these in vitro properties. we and others have investigated the potency of PLGA-MS for T -cell stimulation in the mouse mode!.18-23 With a single injection of MS -OV A/CpG. OVA-specific CTL responses mounting up to 8% of CD8" cells could be obtained; the CTL responses mediated lysis of target cells in vivo and in vitro. production of IFN-y and protection of mice from infection with vaccinia virus. 18 In our study. we tested the antitumor response achievable with PLGA-MS and compared it systematically with an IFA formulation. We found that PLGA-MS-based immunotherapy elicited long-lasting antibody titers. cytolytic and T-helper cell responses and protected mice from growth of melanoma and thymoma in a protective and therapeutic setting. The efficacy was equivalent or even better than that achieved with IFA. which underlines the potential of PLGA-MS for immunotherapy of cancer.
Material and Methods

Preparation of microspheres
Microspheres (MS) were prepared from 14-kDa PLGA 50:50 (Resomer RG502H. Boehringer Ingelheim. lngeiheim. Germany). The antigens and TLR ligands were microencapsulated by spray drying as described elsewhere. I S Briefly. 50 mg ovalbumin (OVA. Grade V. Sigma) and 5 mg CpG oligodeoxynucleotides with a phosphothioate backbone (CpG-ODN 1826. Microsynth. Balgach. Switzerland) or 0.5 mg polyI:C (Calbiochem. VWR. Dietikon. Switzerland) (MS polyI:C) were dissolved in 0.5 ml 0.1 M NaHCO J (aqueous phase) and mixed with 1 g of PLGA dissolved in 20 ml of dichloromethane (organic phase). The two phases were emulsified by ultrasonication (Hielscher. UP200 H. Amp!. 40%) for 10 sec on ice. The obtained w/o dispersion was immediately spray dried (Buchi. Mini Spray-Dryer 191. Buchi. Flawil. Switzerland) at a flow rate of 2 mllmin and inlet/outlet temperatures of 40°C/37°C. The obtained MS were within a size range of 0.5-5 ~un for all batches; they were washed out of the spray-dryer's cyclone with 0.05% poloxamer 188 (SynperonidIDF68. Serva Electrophoresis. Heidelberg. Germany).
collected on a cellulose acetate membrane filter and dried under reduced pressure (20 mbaI') for 18 hr at room temperature. The encapsulation efficacy of OVA in MS -OVA/CpG was determined to be 47% ± 2% according to a previously described protocol.
l H The release of polyI:C from MS-polyl:C was determined to be 37.8% ± 6.6%. PLGA-MS were stored under desiccation at 4°C. Immediately before use. MS were dispersed in PBS by ultrasonication for 30 sec. mice, a number of 5 x 10 5 EG-7 or MO-5 cells, which we titrated to yield optimal tumor growth, were injected subcutaneously into the right flank. Mice were either treated 6 days earlier (protective setting) or as soon as palpable tumor occurred (therapeutic setting). For lung metastasis in the protective setting,S x 10 4 melanin-expressing MO-5 cells were injected into the tail vein at Day 6 after treatment. After 14 days, mice were sacrificed, lungs were removed and visible metastases were counted. Therapeutic treatment of lung metastases started 1 week after inoculation with 2 x 10" melanin-expressing MO-5 cells via the tail vein. and mice were sacrificed after 2 additional weeks.
Mice and immunizations
Intracellular cytokine staining and MHC tetramer staining
Splenocytes were isolated and incubated with or without 10 flM SIINFEKL peptide (Eurogentec. Cologne) in the presence of brefeldin A (10 flg/ml, Sigma-Aldrich) for 5 hr at 37°C. After washing, cells were stained with PE-Cy5-conjugated anti-mouse CD8~ antibody (BD Biosciences Pharmingen, Clone 53-6.7) for 20 min at 4°C. The cells were washed and fixed with 4% para formaldehyde in PBS for 10 min at room temperature. After washing the cells twice with PBS. cells were labeled intracellularly ' with FITC-conjugated rat anti-IFN-y antibody (clone XGM1.2, diluted in PBS/O.l% saponin) at 4°C overnight. The next day, cells were washed and resuspended in PBS for flow cytometry. Background levels of each sample (without peptide) were subtracted. The H-2K b / SIINFEKL tetramers used in our study were kindly provided by Prof. Dirk Busch (TU Munich). For MHC tetramer staining. splenocytes were stained with PE-labeled SIINFEKLlH-2K b -tetramer for 20 min at 37°C and subsequently with PECy5-conjugated rat anti-CD8 IgG for 20 min at 4°C. Cells were washed twice and measured by flow cytometry.
In vivo cytotoxicity assay CTL activity in vivo was assessed exactly as described elsewhere. 28 The percentage of specific cytolysis was calculated as follows: 100 -[(% peptide pulsed cells in vaccinated mice/% unpulsed cells in vaccinated mice)/(% peptide pulsed cells in control mice/% unpulsed cells in control mice)] x 100.
Ex vivo cytotoxicity assays
For the classical chromium release assay ( Fig. Sa) , C57BLl6 mice were immunized either by a mixture of PLGA-MS or the corresponding components in IFA. Six days later, splenocytes were used as effectors in a primary chromium release assay as previously described. 29 EL-4 (H-zl') (negative control) or EG-7 cells served as targets. For measurement of ex vivo cytolytic activity of splenocytes from vaccinated C57BLI 6 mice in Figure 5b , a time-resolved fluorometric assay based on the DELFIA® EuTDA reagent (PerkinElmer) was used. 
ELISA
For detection of OVA-specific immunoglobulin (Ig) in plasma, blood samples were collected at indicated time points after immunization using a heparin-coated microvette (Sarstedt, Numbrecht. Germany) and spun down for 5 min at 1,000g. Ninety-six-well ELISA plates were coated with 0.1 mg/ml OVA in PBS overnight at 4°C. The next day. plates were washed three times with PBS-Tween 20 (0.05%), and serum samples were applied for 2 hr at room temperature. For detection of mouse Ig isotypes. the mouse-Ig-isotyping-kit (BD Bioscience) was used. For detection of IL-4 and IFN-y, the respective kit (mouse IFN-y/IL-4 ELISA set, BD Bioscience) was used. following the manufacturer's instruction. (Fig. I) . Empty MS showed no significant increase of Ig isotypes within 4 weeks (data not shown).
Proliferation assay
The maximum concentration of about 18 Ilg/ml of OVA-specific IgG I and IgG2a was reached after 3 weeks and stayed at that level until the end of the experiment after 5 weeks post-MS-based vaccination, whereas we observed a marked decline of the titers after the 5th week when IFA-based immunization was performed. The relative levels of OVA-specific IgG 1 to IgG2a suggested a balanced Thl/Th2 response.
Enhancement of CTL responses by TNF-IX pretreatment and prime-boost vaccination
We tested two options to enhance the CTL response to PLGA-MS: (i) by pretreatment of the injection site with TNF-CX 3 1 and (ii) by administering a booster injection. The pretreatment of the injection site with 200 ng TNF-cx at least 6 hr before immunization increased the CTL response markedly, and this effect was still visible when the pretreatment was performed up to 8 hr before immunization (Fig. 2a) . Homologous priming-boosting with MS-OV A/CpG within an interval of 4 weeks failed to increase OVA-specific CTL responses, as determined by intracellular IFN-y staining (ICS), whereas a heterologous boosting using recombinant vaccinia virus expressing OVA improved the CTL response (Fig. 2b) . Flow cytometric analysis with SIINFEKLlH-2K b tetramers confirmed the enhanced response after heterologous as opposed to homologous boosting with MS-OV A/CpG, but this read-out evidenced also an effect of a homologous boosting (MS-MS) (Fig. 2c) . It was noteworthy that not all tetramer+CD8+ cells obtained after homologous boosting (MS-MS) also showed IFN-y production in the ICS.
IFN-y but no IL-4 production by CD4 + splenocytes from PLGA-MS-vaccinated mice
The propensity for Th j as opposed to Th2 differentiation after MS-based immunization was further characterized by the IL-4 and IFN-y concentrations in the supernatant of splenocytes harvested from mice, either immunized with MS-OV A/ CpG or a formulation of the same substances in IFA. As a control, we used MS or IFA containing CpG oligonucleotides alone. Subsequent to stimulation with anti-CD3 and anti-CD28 antibodies in vitro, the supernatants of both splenocyte preparations contained predominantly IFN-y and barely detectable levels of IL-4, arguing for a Thl bias conferred by both vaccination modes (Fig. 3) .
Persistence of cn and T-helper cell stimulation after
PLGA-MS-and IFA-based vaccination
As PLGA-MS and IFA are expected to create a depot of antigen at the site of injection, we investigated the potential of PLGA-MS-and IFA-based vaccination to induce in vivo proliferation of OVA-specific CD8+ and CD4 1 -T cells derived from OT-I and OT-2 mice at several time points after vaccination. To this aim, we vaccinated the mice with either a mixture of MS-OV A/CpG and MS-polyl:C, which we determined to be the most potent vaccination scheme (M. Mueller, unpublished data), or the same amounts of OVA, CpG oligos and polyl:C in IFA. Following CFSE dilution assays, both PLGA-MS-and IFA-based vaccination induced the proliferation of transferred CD4+ and CD8 "' T cells in vivo even when the T-cell transfer occurred up to 21 days after inoculation (Figs. 4a and 4b) .
In vivo and ex vivo cytotoxicity elicited by PLGA-MS-and IFA-based vaccination
The cytotoxic effect of the generated CTLs was assessed by in vivo and ex vivo assays. .z.. either a mixture of MS-OV A/CpG and MS-polyl:C or the same amounts of OVA, CpG oligos and polyl:C in IFA, the IFA formulation elicited a slightly superior ex vivo cytotoxicity in the 51 -chromium cytotoxicity assay at effector to target ratios of 30:1 and 10:1 than the PLGA-MS formulation (Fig. Sa) . However, in the nonradioactive EuBATDA cytotoxicity assay, the PLGA-MS-and IFA-based vaccinations elicited similar cytolytic responses, yielding a detectable cytolytic response ex vivo even 14 days after immunization (Fig.  Sb) . The in vivo cytotoxicity assay showed robust responses at 6 days after PLGA-MS-and IFA-based vaccinations, which remained detectable when target cells were injected 9, 16 or even 21 days after vaccination, thus indicating that both vaccine formulations yielded long-lasting cytotoxic responses (Fig. Se) .
Tumor eradication by PLGA-MS-and IFA-based immunotherapy
For comparing the potential of PLGA-MS-and IFA-based vaccination for tumor immunotherapy, we investigated the antitumor responses to EL-4 thymoma (Fig. 6a) as well as to the very aggressive and fast growing B16FI0 melanoma (Fig.  6b) . The corresponding OVA transfectants EG-? and MO-S were used in either a protective setting (Fig. 6 , left-hand side panels), where therapy was started 6 days before challenge, or in a therapeutic setting (Fig. 6 , right-hand side panels), where therapy was started not before palpable tumors had been established. Eighty percent of mice receiving treatment with a mixture of MS-OV A/CpG and MS-polyl:C in a protective setting survived tumor free using EG-? model, and all MS-treated mice survived in the protective MO-S model. For comparison, all mice being treated with IFA containing the same ingredients remained tumor free in the EG-? model, but only 60% survived inoculation with MO-S tumor cells. The therapeutic settings showed that both delivery systems had the potency to cure all mice from EG-7 tumors. For MO-S, however, only 20% of the PLGA-MS group and 30% of the IFA group survived tumor free. In a further assay, metastases in the lung were established by i.v. injection of melanin-producing MO-S cells. Here, both IFA and PLGA-MS formulations markedly reduced the number of metastases in the protective setting (Fig. 6e) ... showed a clear benefit for the group being treated with PLGA-MS when compared to the IFA group. Taken together, we could show that vaccination with PLGA-MS stimulates a robust immune response that has the potency to eradicate solid tumors and to prevent metastasis formation at an extent equivalent or superior to that of IFA.
Discussion presentation by DC. In the last decade, great efforts have been invested to cultivate autologous human DC in vitro to pulse them with antigen and inject them into patients .. 12 -.16 This approach, besides yielding largely disappointing clinical results, is very labor and cost intensive. An interesting alternative is the in vivo delivery of antigens and immunostimulants to DC for which IFA formulations have been used most frequently. The pivotal function of DCs for T-cell priming has spurred tremendous efforts to target tumor antigens for uptake and Admittedly, IFA formulations have been improved in terms of safety and tolerance by the patients. MF-59, e.g., is an emulsified squalene in combination with Tween and Span8S, a fatty acid ester of polyhydric alcohol, which stabilizes the water in oil emulsion. Besides alum, MF-S9 is the only carrier system approved for clinical use in humans. 37 ,38 Nevertheless, both alum and MF-S9 are known to favor Th2 responses and show poor efficacy in regard to antigen or adjuvant depot formation .
3 '),1u In combination with Thl-polarizing adjuvants like monophosphoryl lipid A (MPL),11 a detoxified LPS derivate binding TLR442 or QS-21,'13 a subfraction of QUil-A, both have been successfully used in malaria vaccines, in HPV as well as in HIV studies: '0 ,44-46 In our study, we investigated the potency of PLGA-MS based vaccination in immunotherapy of mice against two model tumors. We showed that PLGA-MS were equal or superior to IFA-based vaccination currently used in clinical trials.
5 ,4 7,48 A major rationale for developing PLGA-MS as antigen delivery systems resided on their capacity to elicit strong antibody responses after a single administration without the need of booster immunizations 49 We could also show that high titers of OVA-specific IgG 1 and IgG2a are obtained by a single vaccination and that these titers are maintained for several weeks (Fig. 1) . Systemic IgE levels remained low arguing against an enhanced risk of allergiC reactions. We hypotheSized that the slow biodegradation of PLGA-MS over several weeks would allow the maintenance of an antigen depot, which might sustain CTL responses over an extended period of time. Indeed, the T-cell transfer experiments demonstrated that both IFA-and PLGA-MS-based vaccinations sustain antigen presentation for over 21 days in vivo (Fig. 4) . More importantly, the induced CTLs were capable to lyse antigen-charged cells for up to 21 days after immunization. This result came as a surprise, because we had previously shown by IFN-y ICS that PLGA-MS-based vaccination led to a peak of IFN-y-producing CD8'" cells on Day 6 after vaccination and declined rapidly thereafter. I S Hence, the capacity to lyse target cells is sustained longer than that of producing IFN-y. We were concerned that the persistence of antigen in PLGA-MS would induce regulatory T cells, but no accumulation of CD4+CD2S +FOXP3+ T cells was observed over time following PLGA-MS-based vaccination (M. Mueller, unpublished data) . Consistently, IFN-y production and the switch to IgG2a was much more prominent after IFA-or PLGA-MS-based vaccination than IL-4 production or the switch to IgE. It References therefore appears that both formu lations induce a Thl differentiation, which is probably due to CpG oligo and polyI:C coadministered with the antigen. In our efforts to optimize PLGA-MS -based vaccination, two parameters turned out to be helpful for enhancing the Th, responses to PLGA-based vaccination: (i) the preconditioning of the injection site with TNF-a? ' and (ii) the use of two different pattern molecules, CpG and polyl:C. Also, the capacity to maintain IFN-y production by antigen-specific CD8+ cells by a heterologous boost with recombinant vaccinia virus is an important finding of our study, which could be explOited in clinical trials. Both the ability of CTLs to directly lyse tumor cells as well as the production of IFN-y by CTL and Thl cells will most likely contribute to the observed antitumor responses (Fig. 6) .
Finally, it is interesting to compare the efficacy of the antitumor response of PLGA-MS-and IFA-based vaccination. Although both vaccination regimes mediated the complete eradication of well-palpable EG-7 thymomas (Fig. 6a) , the protection against this tumor and the aggreSSive MO-S melanoma was enhanced when PLGA-MS-based vaccination preceded tumor inoculation. Also, the suppression of metastasis formation in the lung after MO-S inoculation was clearly stronger when PLGA-MS based vaccination was used in a therapeutic setting (Fig. 6c) . Our tumor protection and immunotherapy data are consistent with other tumor vaccination studies using PLGA nanoparticles or microparticies containing protein antigens and TLR ligands, which showed that the coencapsulation of antigen and pattern molecules markedly improves the antitumor response 21 and even allowed the enidication of preexisting B16FI0 melanoma. '9 Taken together, PLGA-MS-based vaccination combines excellent biocompatibility with high and long-lasting antitumor responses resulting in powerful tumor eradication in mice. Therefore, the investigation of PLGA-MS-based vaccination in a phase 1 clinical trial of immunotherapy against cancer is clearly warranted.
